Tempus AI, Inc. and Medtronic plc announced on April 1 2026 that the ALERT (Addressing undertreatment and health equity in aortic stenosis and mitral regurgitation using an integrated EHR platform) trial, presented at the American College of Cardiology’s 75th Annual Scientific Session & Expo on March 28‑30 2026, showed a 27 % increase in the likelihood that patients with significant valvular heart disease receive timely evaluation by a multidisciplinary heart team or undergo a valve intervention compared with usual care.
The multicenter, cluster‑randomized study enrolled patients with aortic stenosis and mitral regurgitation across a range of hospitals and used AI‑driven electronic health record alerts to prompt clinicians. The intervention arm saw a 40 % relative rise in valve procedures and a 27 % rise in multidisciplinary heart team evaluations within 90 days, translating into a measurable reduction in the time from diagnosis to intervention. The device‑agnostic alert system was designed to integrate seamlessly with existing EHR workflows, ensuring that the improvement was driven by a scalable, technology‑enabled process rather than a single product launch.
These results reinforce Medtronic’s commitment to expanding its digital health portfolio and underscore the company’s strategy of embedding AI into clinical pathways to improve patient outcomes. By demonstrating that AI alerts can reduce clinical inertia and accelerate care, the trial provides evidence that Medtronic’s integrated cardiovascular solutions can deliver tangible benefits across diverse patient populations, including women, older adults, racial and ethnic minorities, and rural residents—groups historically underserved in valvular heart disease care.
The ALERT trial’s success is expected to inform future product development and clinical practice guidelines, positioning Medtronic as a leader in integrated cardiovascular care solutions. For Tempus AI, the partnership highlights the company’s role in providing the AI analytics that power the alert system, further solidifying its position as a key enabler of data‑driven care pathways in cardiology. Together, the two companies demonstrate how collaboration between a medical device manufacturer and an AI analytics firm can accelerate the adoption of evidence‑based, equitable care for patients with valvular heart disease.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.